Appointments at PENTAX Medical

Montvale, New Jersey – PENTAX Medical officials announce that Mark Koppel, M.D., will join the organization as chief medical officer of the Americas. In this position, Mark will be responsible for strengthening PENTAX Medical’s interface between our products, our patients, and the medical community.

“Mark’s background as both a medical doctor and an attorney strengthens our PENTAX Americas leadership and organizational capabilities as we deliver our current business initiatives and make sure we are in the best position possible to serve our customers,” said Chris Burton, PENTAX president of the Americas. 

Koppel is a healthcare executive with more than a decade of both clinical and commercial experience. Most recently, he was the chief medical officer at Health Sciences Outcomes. Previously, he held positions including resident physician at Rush University Medical Center and Resurrection Medical Center, and also brings to the table extensive sales and marketing experience from his time at General Electric. He earned his MD degree at the University of Tennessee, College of Medicine, and holds a JD degree from the University of Arkansas School of Law. 

PENTAX Medical is also pleased to announce that Gene Merante has been appointed chief operating officer (COO) of the Americas, a position he will take on in addition to his current role as chief financial officer (CFO/EVP) of the Americas. In his new role, Merante will be instrumental in leading and ensuring the Americas region operates in the most efficient manner possible. “We look forward to harnessing Merante’s industry experience and ability to guide our organization well beyond the area of finance,” Burton notes. 

Merante joined PENTAX Medical in 2006 as vice president of finance and since that time has taken on increasing levels of responsibility. He was promoted to vice president and treasurer for PENTAX of America Inc. and PENTAX Canada, Inc. in 2008, and was named CFO and executive vice president for the Americas in 2010.

Source: PENTAX Medical